Sector News

GSK CEO Andrew Witty says drugmakers need to be empathetic

September 19, 2016
Life sciences

Drugmakers need to learn empathy and not try to defend price hikes that make drugs inaccessible, Andrew Witty, the chief executive of British pharmaceutical giant GSK, told CNBC.

“In all circumstance, we need to be realistic and empathetic, we need to demonstrate better that we understand people are concerned about [drug pricing],” Witty told CNBC on the sidelines of the Singapore Summit 2016.

“I’m not, for a second, going to sit here and defend any historical pricing position,” he added.

Drug prices have come under scrutiny in recent months after Mylan received public backlash for the sharp price increases the Epipen, an injection device to treat fatal anaphylactic shocks from food allergies or insect bites. The price of a two-pack Epipen has risen to nearly $600, from just $100 in 2007.

Pharmaceutical companies have also been a favorite target of both Democrat candidate Hillary Clinton and GOP nominee Donald Trump during the 2016 presidential elections campaign.

Trump has even commented about the potential savings that the U.S. Medicare program could reap if it negotiates directly with drug-makers, something currently prohibited by law. Last September, Clinton tweeted about the “price gorging” of Daraprim, a treatment often used by HIV/AIDS patients, drawing attention to Martin Shkreli, the former CEO of Turing Pharmaceuticals which owns the drug.

“There is a real issue here on affordability… it almost doesn’t matter whether or not you can defend the price because if people can’t afford it, that’s what we have to focus on,” Witty said.

“[Drug] pricing always has to be taken in a very responsible mindset to get the balance right between access and reward for innovation,” he added.

By Pauline Chiou and Aza Wee Sile

Source: CNBC

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach